The stock of ReShape Lifesciences Inc (RSLS) has seen a -32.61% decrease in the past week, with a -76.11% drop in the past month, and a -86.62% decrease in the past quarter. The volatility ratio for the week is 17.01%, and the volatility levels for the past 30 days are at 17.89% for RSLS. The simple moving average for the last 20 days is -50.10% for RSLS’s stock, with a simple moving average of -89.90% for the last 200 days.
Is It Worth Investing in ReShape Lifesciences Inc (NASDAQ: RSLS) Right Now?
Moreover, the 36-month beta value for RSLS is 1.35. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RSLS is 2.71M and currently, short sellers hold a 3.06% of that float. On March 11, 2025, RSLS’s average trading volume was 1.09M shares.
RSLS) stock’s latest price update
The stock of ReShape Lifesciences Inc (NASDAQ: RSLS) has decreased by -18.83 when compared to last closing price of 0.90.Despite this, the company has seen a loss of -32.61% in its stock price over the last five trading days. globenewswire.com reported 2025-03-10 that Vagal Neuromodulation Provides Route to Treat Type 2 Diabetes and Hypoglycemia Vagal Neuromodulation Provides Route to Treat Type 2 Diabetes and Hypoglycemia
RSLS Trading at -76.70% from the 50-Day Moving Average
After a stumble in the market that brought RSLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.47% of loss for the given period.
Volatility was left at 17.89%, however, over the last 30 days, the volatility rate increased by 17.01%, as shares sank -74.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -82.76% lower at present.
During the last 5 trading sessions, RSLS fell by -32.61%, which changed the moving average for the period of 200-days by -93.99% in comparison to the 20-day moving average, which settled at $1.4721. In addition, ReShape Lifesciences Inc saw -83.53% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RSLS starting from STANKOVICH THOMAS, who sale 48 shares at the price of $0.25 back on May 31 ’24. After this action, STANKOVICH THOMAS now owns 22,777 shares of ReShape Lifesciences Inc, valued at $12 using the latest closing price.
Stock Fundamentals for RSLS
Current profitability levels for the company are sitting at:
- -0.97 for the present operating margin
- 0.68 for the gross margin
The net margin for ReShape Lifesciences Inc stands at -0.86. The total capital return value is set at -4.98. Equity return is now at value -309.28, with -105.15 for asset returns.
Based on ReShape Lifesciences Inc (RSLS), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -32.45.
Currently, EBITDA for the company is -14.48 million with net debt to EBITDA at 0.07. When we switch over and look at the enterprise to sales, we see a ratio of 0.23. The receivables turnover for the company is 6.09for trailing twelve months and the total asset turnover is 1.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.33.
Conclusion
To wrap up, the performance of ReShape Lifesciences Inc (RSLS) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
